A team of Unite2Cure representatives met on Friday January 15th with MEP Glenis Wilmott, who has been actively involved in promoting changes to the Paediatric Medicines Regulation (PMR) in order to speed up the development of new drugs for kids with cancer.
Ms. Wilmott was able to provide some insight into the legislative process, but in particular, what MEPs can do to push the process forward. It is clear that what is required is a straightforward and relatively simple proposal on changes to the PMR. Framing something of this kind will be our goal during the Cancer Drug Development Forum (CDDF) congress this week in Brussels. It was also agreed that ideally a balanced set of proposals with toughening up of requirements on mechanism of action combined with some new incentives on the lines of those framed by WG2 would appear attractive.